
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts

European Health Resilience: Strengthening Preparedness Amidst Geopolitical Challenges
EFPIA and Vaccines Europe endorse the European Commission’s Communication titled “Reinforcing Global Health Resilience Amidst Geopolitical Change,” published on 13 May, as a constructive advancement in bolstering European Health Resilience within a fragmented global environment. The statement hig...

SAHPRA SAPC Regulatory Enforcement: Addressing Unregistered GLP-1 and GIP Products
SAHPRA SAPC regulatory enforcement has intensified following the seizure of all GLP-1 and GIP injectable products at iDexis (Pty) Ltd trading as Sentra Pharmacy. An inspection on 11 May 2026 revealed the facility was manufacturing and distributing unregistered medicines containing semaglutide, ti...

Impact of MDR Software Regulations on Medical Device Innovation
MDR software regulations under the EU’s Medical Device Regulation (EU 2017/745) are creating heavy operational and financial pressures, according to a survey of 35 SaMD manufacturers listed in the EUDAMED database. Financial burdens hit 88.6 % of respondents at significant or severe levels, while...